Gibson Dunn Advises Galecto, Inc. on Establishing At-the-Market Facility for Sale of up to $150 Million of Common Stock

Firm News  |  February 12, 2026

---

Gibson Dunn represented Galecto, Inc. in establishing an at-the-market facility for the sale of up to $150 million of shares of its common stock.

Galecto is a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers.

Gibson Dunn regularly advises biopharmaceutical companies on at-the-market equity offerings and other capital markets transactions.

The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Nicholas Linke, Lauren Navarro, and Anika Gidwani.